InflaRx (IFRX) Research & Development (2016 - 2026)
InflaRx (IFRX) posted Research & Development of -$4.9 million for Q1 2026, down 109.08% sequentially from $53.8 million in Q4 2025, and up 33.84% YoY from -$3.6 million in Q1 2025.
InflaRx (IFRX) Research & Development (2016 - 2026) Analysis & Trends
InflaRx has reported Research & Development for 11 years, with the latest figure at -$4.9 million in Q1 2026.
- Quarterly Research & Development rose 33.84% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.4 million (down 11.57% YoY) and the FY2025 annual result came in at $29.1 million, down 24.08% from the prior year.
- Research & Development declined to -$4.9 million in Q1 2026 per IFRX's latest filing, from $53.8 million in the prior quarter.
- Over five years, Research & Development peaked at $79.6 million in Q4 2023 and troughed at -$15812.4 billion in Q1 2023.
- A 5-year average of -$930.1 billion and a median of -$7.9 million in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 1035.95% in 2023, down 134538545.21% in 2023.
- Over 5 years, Research & Development stood at -$8.5 million in 2022, then surged by 1035.95% to $79.6 million in 2023, then dropped by 14.32% to $68.2 million in 2024, then declined by 21.18% to $53.8 million in 2025, then sank by 109.08% to -$4.9 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$4.9 million, $53.8 million, and -$7.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | -5.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.88 Mn |
| Dec 31, 2025 | 53.76 Mn |
| Sep 30, 2025 | -7.30 Mn |
| Jun 30, 2025 | -8.15 Mn |
| Mar 31, 2025 | -7.38 Mn |
| Dec 31, 2024 | 68.20 Mn |
| Sep 30, 2024 | -12.23 Mn |
| Jun 30, 2024 | -10.79 Mn |
| Mar 31, 2024 | -7.93 Mn |
| Dec 31, 2023 | 79.60 Mn |
| Sep 30, 2023 | -7.95 Mn |
| Jun 30, 2023 | -11.89 Mn |
| Mar 31, 2023 | -15,812.37 Bn |
| Dec 31, 2022 | -8.50 Mn |
| Sep 30, 2022 | -7.60 Mn |
| Jun 30, 2022 | 11.93 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -40,837.37 Bn |
| Sep 30, 2021 | -11.04 Mn |
| Jun 30, 2021 | 13.61 Mn |